Lack of effects of guanfacine on executive and memory functions in healthy male volunteers
- PMID: 16078088
- DOI: 10.1007/s00213-005-0078-4
Lack of effects of guanfacine on executive and memory functions in healthy male volunteers
Abstract
Rationale: Guanfacine is an alpha2-adrenergic receptor agonist that has been shown to have beneficial effects on working memory and attentional functions in monkeys and in patients with attention deficit hyperactivity disorder.
Objectives: The aim of this study was to further investigate the cognitive-enhancing properties of guanfacine using an established battery of tasks measuring executive and memory functions.
Methods: Sixty healthy male volunteers were randomised into three groups. Cognitive testing was performed from +2 to +4 h after double-blind administration of a single oral dose of 1 or 2 mg of guanfacine or placebo.
Results: Systolic blood pressure was significantly reduced by both doses of guanfacine at the end of the testing session. There were no statistically significant effects on any of the cognitive measures. Two trend effects were observed with poorer performance on digit span backward and slower 'Go' reaction times after guanfacine.
Conclusion: This study found no improvement of prefrontal memory or executive functions after guanfacine. Negative effects on blood pressure and trend effects on digit span backward and go reaction time indicate a mild sedative effect of guanfacine at these doses, possibly via mechanisms of autoreceptor down-regulation.
Similar articles
-
Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals.J Psychopharmacol. 2015 Mar;29(3):312-23. doi: 10.1177/0269881114562464. Epub 2015 Jan 7. J Psychopharmacol. 2015. PMID: 25567555 Free PMC article. Clinical Trial.
-
Guanfacine, but not clonidine, improves planning and working memory performance in humans.Neuropsychopharmacology. 1999 May;20(5):460-70. doi: 10.1016/S0893-133X(98)00127-4. Neuropsychopharmacology. 1999. PMID: 10192826 Clinical Trial.
-
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.Clin Ther. 2007 Sep;29(9):1967-79. doi: 10.1016/j.clinthera.2007.09.020. Clin Ther. 2007. PMID: 18035196 Clinical Trial.
-
Guanfacine's mechanism of action in treating prefrontal cortical disorders: Successful translation across species.Neurobiol Learn Mem. 2020 Dec;176:107327. doi: 10.1016/j.nlm.2020.107327. Epub 2020 Oct 17. Neurobiol Learn Mem. 2020. PMID: 33075480 Free PMC article. Review.
-
Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd).Actas Esp Psiquiatr. 2016 May;44(3):107-12. Epub 2016 May 1. Actas Esp Psiquiatr. 2016. PMID: 27254403 Review.
Cited by
-
The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders.Br J Pharmacol. 2011 Oct;164(4):1301-21. doi: 10.1111/j.1476-5381.2011.01323.x. Br J Pharmacol. 2011. PMID: 21410459 Free PMC article. Review.
-
A computational psychiatry approach identifies how alpha-2A noradrenergic agonist Guanfacine affects feature-based reinforcement learning in the macaque.Sci Rep. 2017 Jan 16;7:40606. doi: 10.1038/srep40606. Sci Rep. 2017. PMID: 28091572 Free PMC article.
-
Noradrenergic modulation of working memory and emotional memory in humans.Psychopharmacology (Berl). 2006 Nov;188(4):397-407. doi: 10.1007/s00213-006-0391-6. Epub 2006 Apr 27. Psychopharmacology (Berl). 2006. PMID: 16642355 Review.
-
Guanfacine extended-release: in attention deficit hyperactivity disorder.Drugs. 2010 Sep 10;70(13):1693-702. doi: 10.2165/11205940-000000000-00000. Drugs. 2010. PMID: 20731476 Review.
-
Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action.Neuropsychol Rev. 2007 Mar;17(1):61-72. doi: 10.1007/s11065-006-9017-3. Neuropsychol Rev. 2007. PMID: 17242993 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical